









Mercado
/
Acciones
/
nasdaq-abbv
/

AbbVie Inc

ABBV

189.020USD

-0.290-0.15%

Cierre 07/31, 16:00（ET）Cotizaciones retrasadas 15 min

333.86BCap. mercado

80.35P/E TTM



AbbVie Inc

189.020

-0.290-0.15%

Descripción general Compañía Finanzas

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Información de la empresa

Símbolo de cotizaciónABBV

Nombre de la empresaAbbVie Inc

Fecha de salida a bolsaJan 02, 2013

Fundada en2012

Director ejecutivoMr. Robert A. Michael, CPA

Número de empleados55000

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 02

Dirección1 N Waukegan Rd

CiudadNORTH CHICAGO

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064

Teléfono18479327900

Sitio Webhttps://www.abbvie.com/

Símbolo de cotizaciónABBV

Fecha de salida a bolsaJan 02, 2013

Fundada en2012

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-77.61%

Ms. Jennifer L. Davis

Independent Director

2.52K

+91.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

3.42B

25.21%

Immunology-RINVOQ

1.72B

12.64%

Immunology-HUMIRA

1.12B

8.25%

Hematologic Oncology-IMBRUVICA

947.00M

6.97%

Neuroscience-Botox Therapeutic

866.00M

6.37%

Other

5.51B

40.56%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

9.39B

69.13%

International

3.20B

23.56%

All other countries

747.00M

5.50%

Collaboration revenue

245.00M

1.80%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

3.42B

25.21%

Immunology-RINVOQ

1.72B

12.64%

Immunology-HUMIRA

1.12B

8.25%

Hematologic Oncology-IMBRUVICA

947.00M

6.97%

Neuroscience-Botox Therapeutic

866.00M

6.37%

Other

5.51B

40.56%

Estadísticas de accionistas

Actualizado: vie., 21 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.04%

BlackRock Institutional Trust Company, N.A.

5.15%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.17%

JP Morgan Asset Management

2.02%

Other

76.10%

Accionistas

Proporción

The Vanguard Group, Inc.

10.04%

BlackRock Institutional Trust Company, N.A.

5.15%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.17%

JP Morgan Asset Management

2.02%

Other

76.10%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

44.41%

Investment Advisor/Hedge Fund

19.84%

Research Firm

3.16%

Bank and Trust

2.22%

Pension Fund

2.22%

Sovereign Wealth Fund

1.52%

Hedge Fund

0.70%

Insurance Company

0.68%

Family Office

0.20%

Other

25.06%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

5262

1.32B

74.93%

+12.21M

2025Q1

5332

1.32B

74.90%

+11.71M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

2023Q1

4658

1.27B

71.97%

-18.58M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

177.27M

10.04%

+4.12M

+2.38%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

91.03M

5.15%

+950.86K

+1.06%

Mar 31, 2025

State Street Global Advisors (US)

79.96M

4.53%

+341.48K

+0.43%

Mar 31, 2025

Geode Capital Management, L.L.C.

38.25M

2.17%

+1.11M

+2.98%

Mar 31, 2025

JP Morgan Asset Management

35.61M

2.02%

+1.70M

+5.02%

Mar 31, 2025

Capital Research Global Investors

33.51M

1.9%

-475.69K

-1.40%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

25.27M

1.43%

-2.17M

-7.91%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

25.10M

1.42%

+2.62M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

23.25M

1.32%

+571.37K

+2.52%

Mar 31, 2025

Fidelity Management & Research Company LLC

21.43M

1.21%

+4.44M

+26.15%

Mar 31, 2025

ETFs relacionados

Actualizado: dom., 6 de jul

Nombre

Proporción

First Trust Morningstar Dividend Leaders Index Fund

7.32%

First Trust NASDAQ Pharmaceuticals ETF

7.21%

Health Care Select Sector SPDR Fund

6.67%

iShares U.S. Healthcare ETF

6.42%

Proshares Ultra Health Care

6.2%

VanEck Pharmaceutical ETF

6.16%

Fidelity MSCI Health Care Index ETF

5.91%

Goldman Sachs Future Health Care Equity ETF

5.82%

JPMorgan Healthcare Leaders ETF

5.7%

iShares Core High Dividend ETF

5.58%

First Trust Morningstar Dividend Leaders Index Fund

Proporción7.32%

First Trust NASDAQ Pharmaceuticals ETF

Proporción7.21%

Health Care Select Sector SPDR Fund

Proporción6.67%

iShares U.S. Healthcare ETF

Proporción6.42%

Proshares Ultra Health Care

Proporción6.2%

VanEck Pharmaceutical ETF

Proporción6.16%

Fidelity MSCI Health Care Index ETF

Proporción5.91%

Goldman Sachs Future Health Care Equity ETF

Proporción5.82%

JPMorgan Healthcare Leaders ETF

Proporción5.7%

iShares Core High Dividend ETF

Proporción5.58%

Dividendos

Un total de 48.58B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

